MedTrace Logo

Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy

NCT02793687 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-02-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of long-term sequential therapy with Mexidol® in long-term sequential treatment of patients in the acute and early recovery periods of hemispheric ischemic stroke (IS). This is superiority trial that investigates whether Mexidol® better than placebo.

Conditions

Interventions

DRUG

Mexidol

50 mg/ml IV solution, 125 mg tablet

OTHER

Placebo

Placebo IV solution, Placebo tablet

Sponsors & Collaborators

  • Pharmasoft

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-06
Primary Completion
2016-05-27
Completion
2016-05-27

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02793687 on ClinicalTrials.gov